Effect of epigallocatechin-3-gallate on proliferation and phenotype maintenance in rabbit articular chondrocytes in vitro

Huang,Haojia; Liu,Qin; Liu,Lei; Wu,Huayu; Zheng,Li

doi:10.3892/etm.2014.2057

Effect of epigallocatechin-3-gallate on proliferation and phenotype maintenance in rabbit articular chondrocytes in vitro

Authors:
- Haojia Huang
- Qin Liu
- Lei Liu
- Huayu Wu
- Li Zheng
View Affiliations

Affiliations: Graduate School, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Research Center for Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Cell Biology and Genetics, School of Premedical Sciences, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: November 10, 2014 https://doi.org/10.3892/etm.2014.2057
Pages: 213-218

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In autologous chondrocyte implantation (ACI) to restore defective cartilage, limited cell numbers and dedifferentiation of chondrocytes are the major difficulties. An alternative is the use of growth factors, but their high cost and potential for tumorigenesis are major obstacles. To ensure successful ACI therapy, it is important to find an effective substitute pro‑chondrogenic agent. Epigallocatechin‑3‑gallate (EGCG), one of the green tea catechins, has been widely investigated in studies of interleukin‑1β‑induced chondrocytes. In the present study, the effects of EGCG on rabbit articular chondrocytes were investigated through the examination of cell proliferation, morphology, glycosaminoglycan synthesis and cartilage-specific gene expression. The results showed that EGCG could effectively promote chondrocyte growth and enhance the secretion and synthesis of the cartilage extracellular matrix by upregulating expression levels of aggrecan, collagen II and Sox9 genes. Expression of the collagen I gene was downregulated, which showed that EGCG effectively inhibited the dedifferentiation of chondrocytes. Hypertrophy, which may lead to chondrocyte ossification, was also undetectable in the EGCG groups. In conclusion, the recommended dose of EGCG was found to be in the range of 5 to 20 µM, with the most marked response observed with 10 µM. The present study may provide a basis for the development of a novel agent as a substitute for growth factors in the treatment of articular cartilage defects.

View Figures

View References

1	Carranza-Bencano A, García-Paino L, Armas Padrón JR and Cayuela Dominguez A: Neochondrogenesis in repair of full-thickness articular cartilage defects using free autogenous periosteal grafts in the rabbit. A follow-up in six months. Osteoarthritis Cartilage. 8:351–358. 2000. View Article : Google Scholar : PubMed/NCBI
2	Sánchez M, Anitua E, Azofra J, Andía I, Padilla S and Mujika I: Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med. 35:245–251. 2007. View Article : Google Scholar
3	Chung C and Burdick JA: Engineering cartilage tissue. Adv Drug Deliv Rev. 60:243–262. 2008. View Article : Google Scholar
4	Hsieh PC, Thanapipatsiri S, Anderson PC, Wang GJ and Balian G: Repair of full-thickness cartilage defects in rabbit knees with free periosteal graft preincubated with transforming growth factor. Orthopedics. 26:393–402. 2003.PubMed/NCBI
5	Waterfield MD, Scrace GT, Whittle N, et al: Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature. 304:35–39. 1983. View Article : Google Scholar : PubMed/NCBI
6	Josephs SF, Guo C, Ratner L and Wong-Staal F: Human-proto-oncogene nucleotide sequences corresponding to the transforming region of simian sarcoma virus. Science. 223:487–491. 1984. View Article : Google Scholar : PubMed/NCBI
7	Downward J, Yarden Y, Mayes E, et al: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307:521–527. 1984. View Article : Google Scholar : PubMed/NCBI
8	del Peso L, González-García M, Page C, Herrera R and Nuñez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 278:687–689. 1997. View Article : Google Scholar : PubMed/NCBI
9	Rice-Evans CA, Miller NJ and Paganga G: Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med. 20:933–956. 1996. View Article : Google Scholar : PubMed/NCBI
10	Salah N, Miller NJ, Paganga G, Tijburg L, Bolwell GP and Rice-Evans C: Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophys. 322:339–346. 1995. View Article : Google Scholar : PubMed/NCBI
11	Yang CS and Landau JM: Effects of tea consumption on nutrition and health. J Nutr. 130:2409–2412. 2000.PubMed/NCBI
12	Blot WJ, McLaughlin JK and Chow WH: Cancer rates among drinkers of black tea. Crit Rev Food Sci Nutr. 37:739–760. 1997. View Article : Google Scholar
13	Buschman JL: Green tea and cancer in humans: a review of the literature. Nutr Cancer. 31:151–159. 1998. View Article : Google Scholar
14	Kohlmeier L, Weterings KG, Steck S and Kok FJ: Tea and cancer prevention: an evaluation of the epidemiologic literature. Nutr Cancer. 27:1–13. 1997. View Article : Google Scholar : PubMed/NCBI
15	Na HK and Surh YJ: Intracellular signaling network as a prime chemopreventive target of (−)-epigallocatechin gallate. Mol Nutr Food Res. 50:152–159. 2006. View Article : Google Scholar : PubMed/NCBI
16	Bar-Sela G, Epelbaum R and Schaffer M: Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem. 17:190–197. 2010. View Article : Google Scholar : PubMed/NCBI
17	Li Y, Kong D, Wang Z and Sarkar FH: Regulation of microRNAs by natural agents: An emerging field in chemoprevention and chemotherapy research. Pharm Res. 27:1027–1041. 2010. View Article : Google Scholar : PubMed/NCBI
18	Mak JC: Potential role of green tea catechins in various disease therapies: progress and promise. Clin Exp Pharmacol Physiol. 39:265–273. 2012. View Article : Google Scholar : PubMed/NCBI
19	Ahmed S: Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. Arthritis Res Ther. 12:2082010. View Article : Google Scholar : PubMed/NCBI
20	Pandey KB and Rizvi SI: Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2:270–278. 2009. View Article : Google Scholar
21	Mandel SA, Amit T, Weinreb O and Youdim MB: Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J Alzheimers Dis. 25:187–208. 2011.PubMed/NCBI
22	Stangl V, Lorenz M and Stangl K: The role of tea and tea flavonoids in cardiovascular health. Mol Nutr Food Res. 50:218–228. 2006. View Article : Google Scholar : PubMed/NCBI
23	Shanmugam MK, Kannaiyan R and Sethi G: Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr Cancer. 63:161–173. 2011. View Article : Google Scholar : PubMed/NCBI
24	Pan MH, Lai CS, Dushenkov S and Ho CT: Modulation of inflammatory genes by natural dietary bioactive compounds. J Agric Food Chem. 57:4467–4477. 2009. View Article : Google Scholar : PubMed/NCBI
25	Bae JY, Kanamune J, Han DW, Matsumura K and Hyon SH: Reversible regulation of cell cycle-related genes by epigallocatechin gallate for hibernation of neonatal human tarsal fibroblasts. Cell Transplant. 18:459–469. 2009. View Article : Google Scholar : PubMed/NCBI
26	Akhtar N and Haqqi TM: Epigallocatechin-3-gallate suppresses the global interleukin-1beta-induced inflammatory response in human chondrocytes. Arthritis Res Ther. 13:R932011. View Article : Google Scholar : PubMed/NCBI
27	Rasheed Z, Anbazhagan AN, Akhtar N, Ramamurthy S, Voss FR and Haqqi TM: Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther. 11:R712009. View Article : Google Scholar : PubMed/NCBI
28	Ahmed S, Wang N, Lalonde M, Goldberg VM and Haqqi TM: Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther. 308:767–773. 2004. View Article : Google Scholar
29	Buschmann MD and Grodzinsky AJ: A molecular model of proteoglycan-associated electrostatic forces in cartilage mechanics. J Biomech Eng. 117:179–192. 1995. View Article : Google Scholar : PubMed/NCBI
30	Robinson D, Ash H, Yayon A, Nevo Z and Aviezer D: Characteristics of cartilage biopsies used for autologous chondrocytes transplantation. Cell Transplant. 10:203–208. 2001.PubMed/NCBI
31	Akiyama H: Transcriptional regulation in chondrogenesis by Sox9. Clin Calcium. 21:845–851. 2011.(In Japanese). PubMed/NCBI
32	Tew SR and Clegg PD: Analysis of post transcriptional regulation of SOX9 mRNA during in vitro chondrogenesis. Tissue Eng Part A. 17:1801–1807. 2011. View Article : Google Scholar : PubMed/NCBI
33	Ng LJ, Wheatley S, Muscat GE, et al: SOX9 binds DNA, activates transcription, and coexpresses with type II collagen during chondrogenesis in the mouse. Dev Biol. 183:108–121. 1997. View Article : Google Scholar : PubMed/NCBI
34	Marshall OJ and Harley VR: Molecular mechanisms of SOX9 action. Mol Genet Metab. 71:455–462. 2000. View Article : Google Scholar : PubMed/NCBI
35	Davies SR, Chang LW, Patra D, et al: Computational identification and functional validation of regulatory motifs in cartilage-expressed genes. Genome Res. 17:1438–1447. 2007. View Article : Google Scholar : PubMed/NCBI
36	Tew SR, Li Y, Pothacharoen P, Tweats LM, Hawkins RE and Hardingham TE: Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes. Osteoarthritis Cartilage. 13:80–89. 2005. View Article : Google Scholar : PubMed/NCBI
37	Paul R, Haydon RC, Cheng H, et al: Potential use of Sox9 gene therapy for intervertebral degenerative disc disease. Spine (Phila Pa 1976). 28:755–763. 2003. View Article : Google Scholar
38	Tsuchiya H, Kitoh H, Sugiura F and Ishiguro N: Chondrogenesis enhanced by overexpression of sox9 gene in mouse bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun. 301:338–343. 2003. View Article : Google Scholar : PubMed/NCBI
39	Benya PD and Shaffer JD: Dedifferentiated chondrocytes reexpress the differentiated collagen phenotype when cultured in agarose gels. Cell. 30:215–224. 1982. View Article : Google Scholar : PubMed/NCBI
40	Schnabel M, Marlovits S, Eckhoff G, Fichtel I, Gotzen L, Vécsei V and Schlegel J: Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture. Osteoarthritis Cartilage. 10:62–70. 2002. View Article : Google Scholar : PubMed/NCBI
41	Karlsen TA, Shahdadfar A and Brinchmann JE: Human primary articular chondrocytes, chondroblasts-like cells, and dedifferentiated chondrocytes: differences in gene, microRNA, and protein expression and phenotype. Tissue Eng Part C Methods. 17:219–227. 2010. View Article : Google Scholar : PubMed/NCBI
42	Kwan KM, Pang MK, Zhou S, et al: Abnormal compartmentalization of cartilage matrix components in mice lacking collagen X: implications for function. J Cell Biol. 136:459–471. 1997. View Article : Google Scholar : PubMed/NCBI
43	Adcocks C, Collin P and Buttle DJ: Catechins from green tea (Camellia sinensis) inhibit bovine and human cartilage proteoglycan and type II collagen degradation in vitro. J Nutr. 132:341–346. 2002.PubMed/NCBI
44	Vankemmelbeke MN, Jones GC, Fowles C, et al: Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. Eur J Biochem. 270:2394–2403. 2003. View Article : Google Scholar : PubMed/NCBI
45	Andriamanalijaona R, Kypriotou M, Baugé C, et al: Comparative effects of 2 antioxidants, selenomethionine and epigallocatechin-gallate, on catabolic and anabolic gene expression of articular chondrocytes. J Rheumatol. 32:1958–1967. 2005.PubMed/NCBI